The report of Global Parkinson’s Disease Therapeutics market by Type (Levodopa Combination, Dopamine Agonists, Monoamine Oxidase B (Mao-B) Inhibitors, Anticholinergic Drugs, Catechol-O-Methyltransferase (COMT) Inhibitors), Indication (Oral, Transdermal, Subcutaneous and Intestinal Infusion), End Users (Hospital pharmacy, retail pharmacy, online pharmacy) and Region (Asia Pacific, North America, Europe, Latin America, and Middle East Africa) is expected to reach US$ XX Bn by 2026, at a CAGR of 11% during a forecast period.
The levodopa combination segment is expected to grow at the highest XX% CAGR during the forecast period.
The levodopa combination drugs segment is expected to account for the leading share of the global market during the forecast period from 2019 to 2026.Levodopa combination therapy is considered a highly-effective treatment for the motor symptoms associated with Parkinson’s disease and is commonly recommended by physicians across the globe. Carbidopa and levodopa combination therapy is commonly used for management of motor fluctuations in Parkinson’s disease.
The North America dominated the Global Parkinson’s Disease Therapeutics Market in 2018
North America projected to dominate the global Parkinson’s disease therapeutics market in the near future, primarily due to the large base of aging population, high clinical R&D budget to address the unmet needs of Parkinson’s disease, and increase in awareness regarding the disease in these regions. North America is estimated to dominate the global Parkinson’s disease therapeutics market by the end of 2026.
Key players operating the Global Parkinson’s Disease Therapeutics market are CytoSorbents Corporation, RegeneRx Biopharmaceuticals, Inc., Endacea, Inc., Adrenomed AG, GlaxoSmithKline plc, Asahi Kasei Corporation, Cardinal Health, Smith & Nephew plc, ConvaTec, Inc., AstraZeneca, Orion Corporation, CHIESI Farmaceutici S.p.A., and Mylan N.V. Abbvie, Inc., Biogen, Inc.,Boehringer Ingelheim GmbHF, Hoffman-La Roche, GlaxoSmithKline Plc.H. Lundbeck A/SImpax Labs, Inc.Newron Pharmaceuticals SpA, Novartis AG, OrionCorporation, UCB S.A.
Maximize Market Research, a global market research firm with a dedicated team of specialists and data has carried out extensive research about the Global Parkinson’s Disease Therapeutics market. The report encompasses the market by different segments and region, providing an in-depth analysis of the overall industry ecosystem, useful for making an informed strategic decision by the key stakeholders in the industry. Importantly, the report delivers forecasts and share of the market, further giving an insight into the market dynamics, and future opportunities that might exist in the Global Parkinson’s Disease Therapeutics market. The driving forces, as well as considerable restraints, have been explained in depth. in addition to this, competitive landscape describing the strategic growth of the competitors have been taken into consideration for enhancing market know-how of our clients and at the same time explain Global Parkinson’s Disease Therapeutics market positioning of competitors.
Browse the market data Tables and Figures spread through a comprehensive research report and in-depth TOC on “Global Parkinson’s Disease Therapeutics Market”
Contact:
MAXIMIZE MARKET RESEARCH PVT. LTD.
Omkar Heights,
ManikBaug, Vadgaon Bk,
Sinhagad Road, Pune – 411051, Maharashtra, India.
+91 9607195908